Core Viewpoint - Azitra, Inc. has announced a public offering of 16,667,000 shares of common stock at a price of $0.30 per share, aiming to raise approximately $5 million for clinical trials, product development, and general corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at $0.30 per share, with gross proceeds expected to be around $5 million before deductions [1]. - Azitra has granted underwriters a 45-day option to purchase an additional 2,500,000 shares to cover over-allotments at the public offering price [1]. - The offering is expected to close on February 16, 2024, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for clinical trials, product development, research and development, clinical manufacturing, and working capital [1]. Group 3: Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, utilizing engineered proteins and topical live biotherapeutic products [4]. - The company has developed a proprietary platform that includes a microbial library of approximately 1,500 unique bacterial strains, enhanced by AI and machine learning technologies [4].

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,850,267 covering future potential pipeline candidates for indications including ichthyosis vulgaris, titled “Methods and compositions for treating skin disease with recombinant microorganisms.” Travis Whitfill, Azitra’s COO, co-fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock: Par value $0.0001 AZTR NYSE American FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-41705 ...